NKTR - NEKTAR THERAPEUTICS
IEX Last Trade
0.9
-0.370 -41.111%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:56 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$1.27
-0.37
-29.13%
Fundamental analysis
21%
Profitability
0%
Dept financing
17%
Liquidity
75%
Performance
30%
Performance
5 Days
-2.21%
1 Month
-16.72%
3 Months
-21.74%
6 Months
-15.16%
1 Year
78.00%
2 Year
-57.78%
Key data
Stock price
$0.90
DAY RANGE
$0.89 - $1.27
52 WEEK RANGE
$0.52 - $1.93
52 WEEK CHANGE
$76.61
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Howard W. Robin
Region: US
Website: nektar.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nektar.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinomas of the head and neck, and adjuvant melanoma. It is also developing NKTR-358, a cytokine Treg stimulant, in phase 2 clinical trial for the treatment of systemic lupus erythematosus
Recent news